Boundless Bio, Inc. cash flow to debt ratio of -95.16% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Boundless Bio, Inc.'s free cash flow has increased -25.51% from $-63.38M last year to $-47.21M, signaling increasing performance

Boundless Bio, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Boundless Bio, Inc.'s debt has decreased relative to shareholder equity from 0.32 last year to 0.00 today, signaling strengthened financials

Boundless Bio, Inc. has a net cash position, so leverage is healthy.

Boundless Bio, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Boundless Bio, Inc. has insufficient data to evaluate this check.

Boundless Bio, Inc.'s short-term assets of $109.61M exceed its short-term liabilities of $12.54M

Boundless Bio, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Boundless Bio, Inc.'s return on equity of -70.89%, is lower than 15.00%, indicating bad performance

Boundless Bio, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Boundless Bio, Inc. has insufficient public price history to evaluate earnings stability.

Boundless Bio, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Boundless Bio, Inc. has negative free cash flow, indicating cash burn

Boundless Bio, Inc.'s yearly earnings has increased -10.96% since last year from $-65.36M to $-58.20M, signaling increasing performance

Boundless Bio, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -103.08% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Boundless Bio, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Boundless Bio, Inc. has insufficient public price history to evaluate revenue consistency.

Boundless Bio, Inc. has insufficient public price history to evaluate ROE consistency.

Boundless Bio, Inc. has insufficient data to evaluate this check.

Boundless Bio, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Boundless Bio, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Boundless Bio, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Boundless Bio, Inc. has insufficient data to evaluate this check.

Boundless Bio, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Boundless Bio, Inc. has a price-to-book ratio of 0.96x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Boundless Bio, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue